Number 3: The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and ...
Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...
The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...
Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...
On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...
In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...
Number 5: In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in ...
Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback